Nurix Therapeutics, Inc.
NASDAQ:NRIX
24.72 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 76.987 | 38.627 | 29.75 | 17.82 | 31.115 | 37.449 |
| Cost of Revenue
| 13.654 | 10.808 | 6.082 | 66.494 | 45.025 | 40.514 |
| Gross Profit
| 63.333 | 27.819 | 23.668 | -48.674 | -13.91 | -3.065 |
| Gross Profit Ratio
| 0.823 | 0.72 | 0.796 | -2.731 | -0.447 | -0.082 |
| Reseach & Development Expenses
| 181.615 | 184.497 | 116.434 | 66.494 | 45.025 | 40.514 |
| General & Administrative Expenses
| 42.902 | 37.997 | 31.202 | 16.309 | 8.326 | 6.674 |
| Selling & Marketing Expenses
| -6.121 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 36.781 | 37.997 | 31.202 | 16.309 | 8.326 | 6.674 |
| Other Expenses
| -189.148 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 218.396 | 222.494 | 147.636 | 82.803 | 53.351 | 47.188 |
| Operating Income
| -155.063 | -183.867 | -117.886 | -64.983 | -22.236 | -9.739 |
| Operating Income Ratio
| -2.014 | -4.76 | -3.963 | -3.647 | -0.715 | -0.26 |
| Total Other Income Expenses Net
| 11.115 | 3.507 | 0.823 | 1.206 | 0.776 | 0.818 |
| Income Before Tax
| -143.948 | -180.36 | -117.063 | -63.777 | -21.46 | -8.921 |
| Income Before Tax Ratio
| -1.87 | -4.669 | -3.935 | -3.579 | -0.69 | -0.238 |
| Income Tax Expense
| 13.486 | -14.315 | 0.131 | -20.535 | 0.239 | 0.507 |
| Net Income
| -143.948 | -166.045 | -117.194 | -43.242 | -21.699 | -9.428 |
| Net Income Ratio
| -1.87 | -4.299 | -3.939 | -2.427 | -0.697 | -0.252 |
| EPS
| -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EPS Diluted
| -2.65 | -3.42 | -2.73 | -2.76 | -0.56 | -0.59 |
| EBITDA
| -141.409 | -183.867 | -117.886 | -64.983 | -19.882 | -6.751 |
| EBITDA Ratio
| -1.837 | -4.76 | -3.963 | -3.647 | -0.639 | -0.18 |